LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 58

Search options

  1. Article ; Online: Dog Ownership Is the Best Preventive 'Medicine' for Patients.

    Robinson, Lary A

    The American journal of medicine

    2021  Volume 134, Issue 6, Page(s) 710–712

    MeSH term(s) Animals ; Dogs ; Humans ; Pets/microbiology ; Pets/psychology ; Preventive Medicine/instrumentation ; Preventive Medicine/methods ; Preventive Medicine/trends
    Language English
    Publishing date 2021-02-21
    Publishing country United States
    Document type Editorial
    ZDB-ID 80015-6
    ISSN 1555-7162 ; 1873-2178 ; 0002-9343 ; 1548-2766
    ISSN (online) 1555-7162 ; 1873-2178
    ISSN 0002-9343 ; 1548-2766
    DOI 10.1016/j.amjmed.2021.01.033
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Book: Thoracic disorders in the immunocompromised patient

    Robinson, Lary A.

    (Chest surgery clinics of North America ; 9,1)

    1999  

    Author's details Lary A. Robinson, guest ed
    Series title Chest surgery clinics of North America ; 9,1
    Collection
    Language English
    Size X, 266 S. : Ill.
    Publisher Saunders
    Publishing place Philadelphia u.a.
    Publishing country United States
    Document type Book
    HBZ-ID HT010185282
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

  3. Article ; Online: Is 'inflammaging' fuelling severe COVID-19 disease?

    Robinson, Lary A / Pierce, Christine M

    Journal of the Royal Society of Medicine

    2020  Volume 113, Issue 9, Page(s) 346–349

    MeSH term(s) Adolescent ; Adult ; Aged ; Aging ; Betacoronavirus ; COVID-19 ; Coronavirus Infections/complications ; Coronavirus Infections/virology ; Humans ; Inflammation/complications ; Pandemics ; Pneumonia, Viral/complications ; Pneumonia, Viral/virology ; SARS-CoV-2 ; Severity of Illness Index
    Keywords covid19
    Language English
    Publishing date 2020-08-17
    Publishing country England
    Document type Journal Article
    ZDB-ID 6731-3
    ISSN 1758-1095 ; 0141-0768 ; 0035-9157
    ISSN (online) 1758-1095
    ISSN 0141-0768 ; 0035-9157
    DOI 10.1177/0141076820945269
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: Impact of Robotic-Assisted Thoracic Surgery on the Completion of Adjuvant Chemotherapy Following Lung Cancer Resection.

    Abdelghany, Khaled / Robinson, Lary A / Tanvetyanon, Tawee

    Cureus

    2022  Volume 14, Issue 10, Page(s) e30364

    Abstract: Background Adjuvant chemotherapy can further improve treatment outcomes following the resection of non-small cell lung cancer (NSCLC). However, in practice, some patients are unable to tolerate all prescribed chemotherapy. One of the factors which may ... ...

    Abstract Background Adjuvant chemotherapy can further improve treatment outcomes following the resection of non-small cell lung cancer (NSCLC). However, in practice, some patients are unable to tolerate all prescribed chemotherapy. One of the factors which may implicate adjuvant chemotherapy completion is a surgical technique. We investigated the impact of robotic-assisted thoracic surgery (RATS), a form of minimally invasive surgery, on chemotherapy completion. Methods We conducted a retrospective study of NSCLC patients who underwent adjuvant platinum-based chemotherapy at our institution during 2010-2020. The primary outcome of interest was chemotherapy completion, defined as receiving all 4 cycles of chemotherapy. We also performed an exploratory analysis to identify factors associated with chemotherapy completion. Results Analyses included 165 patients: 95 patients underwent traditional thoracotomy, and 70 patients underwent RATS. Baseline characteristics were comparable except for smaller tumor size and lower stage in the RATS group. Median operative time was longer in the RATS group than in the thoracotomy group: 198 vs. 139 minutes,
    Language English
    Publishing date 2022-10-16
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2747273-5
    ISSN 2168-8184
    ISSN 2168-8184
    DOI 10.7759/cureus.30364
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: High Pretreatment DHEA Is Associated with Inferior Immunotherapy Response in Metastatic Non-Small Cell Lung Cancer.

    Zhang, Yumeng / Darville, Lancia / Hogue, Stephanie / Hallanger Johnson, Julie E / Rose, Trevor / Kim, Youngchul / Bailey, Alexis / Gray, Jhanelle E / Robinson, Lary A

    Cancers

    2024  Volume 16, Issue 6

    Abstract: Background: ...

    Abstract Background:
    Language English
    Publishing date 2024-03-14
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2527080-1
    ISSN 2072-6694
    ISSN 2072-6694
    DOI 10.3390/cancers16061152
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Is ‘inflammaging’ fuelling severe COVID-19 disease?

    Robinson, Lary A / Pierce, Christine M

    Journal of the Royal Society of Medicine

    2020  Volume 113, Issue 9, Page(s) 346–349

    Keywords General Medicine ; covid19
    Language English
    Publisher SAGE Publications
    Publishing country us
    Document type Article ; Online
    ZDB-ID 6731-3
    ISSN 1758-1095 ; 0141-0768 ; 0035-9157
    ISSN (online) 1758-1095
    ISSN 0141-0768 ; 0035-9157
    DOI 10.1177/0141076820945269
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  7. Article ; Online: Using "Rebar" to Stabilize Rigid Chest Wall Reconstruction.

    Robinson, Lary A / Grubbs, Deanna M

    The Thoracic and cardiovascular surgeon

    2016  Volume 64, Issue 3, Page(s) 266–269

    Abstract: After major chest wall resection, reconstruction of the bony defect with a rigid prosthesis is mandatory to protect the underlying thoracic organs, and to prevent flail chest physiology. Although many methods have been described for chest wall ... ...

    Abstract After major chest wall resection, reconstruction of the bony defect with a rigid prosthesis is mandatory to protect the underlying thoracic organs, and to prevent flail chest physiology. Although many methods have been described for chest wall reconstruction, a commonly used technique employs a composite Marlex (polypropylene) mesh with methyl-methacrylate cement sandwiched between two layers of mesh (MMS), which is tailored to the defect size and shape. In building construction, steel "rebar" is used to strengthen and reinforce masonry structures. To avoid the initial residual motion of the rigid prosthesis used to reconstruct very large defects, particularly the sternum, we devised a simple technique of adding one or more Steinmann steel pins as "rebar" to strengthen and immediately stabilize the prosthesis to the surrounding ribs and sternum. For the very large defects, particularly over the heart and great vessels, titanium mesh may also be readily added into the sandwich construction for increased strength and to prevent late prosthetic fractures. Short- and long-term results of this inexpensive modification of the MMS reconstruction technique are excellent. This modified MMS tailor-made prosthesis is only one-third the cost of the recently popular prosthetic titanium systems, takes much less operative time to create and implant, and avoids the well-described complications of late titanium bar fracture and erosion/infection as well as loosening of screws and/or titanium bars.
    MeSH term(s) Flail Chest/diagnosis ; Flail Chest/surgery ; Humans ; Male ; Middle Aged ; Polypropylenes ; Radiography, Thoracic ; Ribs/surgery ; Surgical Flaps ; Surgical Mesh ; Thoracic Wall/diagnostic imaging ; Thoracic Wall/surgery ; Thoracoplasty/methods
    Chemical Substances Polypropylenes
    Language English
    Publishing date 2016-04
    Publishing country Germany
    Document type Case Reports ; Journal Article
    ZDB-ID 800050-5
    ISSN 1439-1902 ; 0171-6425 ; 0946-4778 ; 0172-6137
    ISSN (online) 1439-1902
    ISSN 0171-6425 ; 0946-4778 ; 0172-6137
    DOI 10.1055/s-0034-1396933
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Effect of prior antibiotic or chemotherapy treatment on immunotherapy response in non-small cell lung cancer.

    Nyein, Andrew F / Bari, Shahla / Hogue, Stephanie / Zhao, Yayi / Maller, Bradley / Sha, Sybil / Gomez, Maria F / Rollison, Dana E / Robinson, Lary A

    BMC cancer

    2022  Volume 22, Issue 1, Page(s) 101

    Abstract: Background: Treatment outcomes of advanced non-small cell lung cancer (NSCLC) have substantially improved with immune checkpoint inhibitors (ICI), although only approximately 19% of patients respond to immunotherapy alone, increasing to 58% with the ... ...

    Abstract Background: Treatment outcomes of advanced non-small cell lung cancer (NSCLC) have substantially improved with immune checkpoint inhibitors (ICI), although only approximately 19% of patients respond to immunotherapy alone, increasing to 58% with the addition of chemotherapy. The gut microbiome has been recognized as a modulator of ICI response via its priming effect on the host immune response. Antibiotics as well as chemotherapy reduce gut microbial diversity, hence altering composition and function of the gut microbiome. Since the gut microbiome may modify ICI efficacy, we conducted a retrospective study evaluating the effects of prior antibiotic or chemotherapy use on NSCLC patient response to ICI.
    Methods: We retrospectively evaluated 256 NSCLC patients treated between 2011-2017 at Moffitt Cancer Center with ICI ± chemotherapy, examining the associations between prior antibiotic or chemotherapy use, overall response rate and survival. Relative risk regression using a log-link with combinatorial expectation maximization algorithm was performed to analyze differences in response between patients treated with antibiotics or chemotherapy versus patients who didn't receive antibiotics or chemotherapy. Cox proportional hazards models were constructed to evaluate associations between risk factors and overall survival.
    Results: Only 46 (18% of 256) patients used antibiotics prior to and/or during ICI treatment, and 146 (57%) had prior chemotherapy. Antibiotic users were 8% more likely to have worse overall response rate (RR:1.08; CI:0.93-1.26; p = 0.321), as well as a 35% worse overall survival (HR:1.35; CI:0.91-2.02; p = 0.145), although results were not statistically significant. However, prior use of chemotherapy was significantly associated with poor ICI response (RR:1.24; CI:1.05-1.47; p = 0.013) and worse overall survival (HR:1.47; CI:1.07-2.03; p = 0.018).
    Conclusions: Patients receiving antibiotics prior to and/or during ICI therapy might experience worse treatment outcomes and survival than unexposed patients, although these associations were not statistically significant and hence warrant further prospective study. Prior chemotherapy significantly reduced ICI response and overall survival. Antibiotic or chemotherapy exposure may negatively impact ICI response, perhaps through disruption of the eubiotic gut microbiome.
    MeSH term(s) Aged ; Anti-Bacterial Agents/adverse effects ; Antineoplastic Agents/administration & dosage ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/immunology ; Carcinoma, Non-Small-Cell Lung/mortality ; Female ; Gastrointestinal Microbiome/drug effects ; Gastrointestinal Microbiome/immunology ; Humans ; Immune Checkpoint Inhibitors/immunology ; Immune Checkpoint Inhibitors/therapeutic use ; Immunotherapy/mortality ; Lung Neoplasms/drug therapy ; Lung Neoplasms/immunology ; Lung Neoplasms/mortality ; Male ; Middle Aged ; Retrospective Studies ; Survival Rate ; Treatment Outcome
    Chemical Substances Anti-Bacterial Agents ; Antineoplastic Agents ; Immune Checkpoint Inhibitors
    Language English
    Publishing date 2022-01-24
    Publishing country England
    Document type Evaluation Study ; Journal Article
    ZDB-ID 2041352-X
    ISSN 1471-2407 ; 1471-2407
    ISSN (online) 1471-2407
    ISSN 1471-2407
    DOI 10.1186/s12885-022-09210-2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: Durvalumab: a potential maintenance therapy in surgery-ineligible non-small-cell lung cancer.

    Shafique, Michael R / Robinson, Lary A / Antonia, Scott

    Cancer management and research

    2018  Volume 10, Page(s) 931–940

    Abstract: Lung cancer is the most common cancer worldwide and the most common cause of cancer-related death. Non-small-cell lung cancer comprises ~87% of newly diagnosed cases of lung cancer, and nearly one-third of these patients have stage III disease. Despite ... ...

    Abstract Lung cancer is the most common cancer worldwide and the most common cause of cancer-related death. Non-small-cell lung cancer comprises ~87% of newly diagnosed cases of lung cancer, and nearly one-third of these patients have stage III disease. Despite improvements in the treatment of stage IV lung cancer, particularly with the introduction and dissemination of checkpoint inhibitors, very little progress has been made in the treatment of stage III lung cancer. In this article, we discuss the general staging criteria and treatment options for stage III lung cancer. We review how concurrent radiation and chemotherapy can have immunomodulatory effects, supporting the rationale for incorporating immunotherapy into existing treatment paradigms. Finally, we discuss the results of the PACIFIC trial and implications for the treatment of stage III lung cancer. In the PACIFIC trial, adding durvalumab as a maintenance therapy following the completion of chemoradiotherapy improved progression-free survival in patients with locally advanced unresectable stage III lung cancer. On the strength of these results, durvalumab has been approved by the US Food and Drug Administration for use in this setting, representing the first advance in the treatment of stage III lung cancer in nearly a decade.
    Language English
    Publishing date 2018-05-01
    Publishing country New Zealand
    Document type Journal Article ; Review
    ZDB-ID 2508013-1
    ISSN 1179-1322
    ISSN 1179-1322
    DOI 10.2147/CMAR.S148009
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top